Yi Zhang | Tumor Immunology | Best Researcher Award

Published on by Cell Biologist

Prof. Yi Zhang | Tumor Immunology | Best Researcher Award

The First Affiliated Hospital of Zhengzhou University | China

Prof. Yi Zhang is a globally recognized leader in genetically engineered cell therapy and translational immuno-oncology research. Over the past 36 years, he has made pioneering contributions to overcoming major barriers in cell therapy and advancing its clinical applications worldwide. His extensive research has produced 290 SCI-indexed publications, including 11 ESI top 1% highly cited papers, accumulating more than 14,000 citations and an h-index of 66. Prof. Zhang’s groundbreaking innovations include identifying the novel CAR-T therapeutic target CD276 for solid tumors, developing gene-editing technologies to reduce PD-1–mediated immunosuppression, and creating novel cytokines and culture protocols that enhance immune cell stemness and anti-tumor function. He has also led the development of CAR-T cells that normalize tumor vasculature and improve infiltration, significantly enhancing therapeutic efficacy. With 46 invention patents (17 authorized) and over 80 million yuan in technology transfers, his work bridges basic science and clinical application through an integrated “industry-university-research” platform. As principal investigator, he has directed more than 52 clinical trials—29 targeting solid tumors, the highest number globally—resulting in improved outcomes and even clinical cures for advanced cancer patients. His leadership in establishing national standards and safety protocols has also shaped the regulation and global best practices in cell therapy.

Profile: Orcid

Featured Publications:

Gao, Y., Liu, S., Huang, Y., Wang, H., Zhao, Y., Cui, X., Peng, Y., Li, F., & Zhang, Y. (2024, December 3). CAR T cells engineered to secrete IFNκ induce tumor ferroptosis via an IFNAR/STAT1/ACSL4 axis. Cancer Immunology Research.

Huang, Y., Cao, R., Wang, S., Chen, X., Ping, Y., & Zhang, Y. (2025, December 31). In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Human Vaccines & Immunotherapeutics.

Li, J., Wang, D., Zhang, Z., Sun, K., Lei, Q., Zhao, X., Huang, J., Wang, L., & Zhang, Y. (2025, June 1). Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology.

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2025, March 5). Correction: Immunosenescence: A key player in cancer development. Journal of Hematology & Oncology.

Ping, Y., Fan, Q., & Zhang, Y. (2025, February). Modulating lipid metabolism improves tumor immunotherapy. Journal for ImmunoTherapy of Cancer.

Hu, W., Li, F., Liang, Y., Liu, S., Wang, S., Shen, C., Zhao, Y., Wang, H., & Zhang, Y. (2025, January). Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. Journal for ImmunoTherapy of Cancer.

Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Icahn School Of Medicine At Mount Sinai | United States

Alexander Tsankov is a leading researcher in computational biology and cancer genomics, known for his contributions to single-cell and spatial transcriptomics. He holds dual bachelor’s degrees in Plan II Honors and Electrical and Computer Engineering from the University of Texas at Austin, and earned his M.S. and Ph.D. in Electrical Engineering and Computer Science from MIT. His research focuses on understanding the cellular and molecular mechanisms underlying cancer progression and tissue remodeling, with an emphasis on glioblastoma, lung adenocarcinoma, and colorectal cancer. Dr. Tsankov has published extensively in top-tier journals such as Nature, Nature Communications, Cancer Discovery, Nature Genetics, and Immunity. He has authored over 50 peer-reviewed publications, with an h-index of 36 and more than 15,000 citations according to Google Scholar. His work has earned him several prestigious honors, including the NIH NRSA postdoctoral fellowship and the NSF graduate fellowship. Dr. Tsankov frequently serves as a senior or corresponding author, highlighting his leadership in the field of computational oncology and single-cell genomics.

Profile: Google Scholar

Featured Publications:

  • “Learning the cellular origins across cancers using single-cell chromatin landscapes”

  • “Cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma”

  • “Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro”

  • “Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma”

  • “Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches”

  • “Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer”

  • “NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma”

  • “Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations”

  • “Single cell view of tumor microenvironment gradients in pleural mesothelioma”

  • “Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines”

Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Vaclav Ranc | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Vaclav Ranc | Palacký University in Olomouc | Czech Republic

Dr. Václav Ranc is a distinguished analytical chemist and data analyst with over 15 years of experience in academia and applied research. Based in the Czech Republic, he leads a research group at Palacký University Olomouc, specializing in nanotechnology, plasmonic and electronic nanosensors, and advanced analytical techniques. He holds a Ph.D. in Analytical Chemistry and a Habilitation in Physical Chemistry. Dr. Ranc has published over 80 peer-reviewed scientific articles and holds several international patents. He has secured and managed significant EU funding, including Horizon Europe and MSCA projects, showcasing his excellence in both research and project leadership. His expertise spans Raman spectroscopy, mass spectrometry, and LC/GC methods, coupled with data analysis in Python, Matlab, and R. He is a regular presenter at international conferences and a recognized innovator in the fields of biosensing and nanomaterials.

Publication Profiles: 

Google Scholar
Orcid
Scopus

Education:

Dr. Václav Ranc earned his MSc. in Analytical Chemistry from Palacký University Olomouc (UPOL) in 2005, where he focused on the discrimination of enantiomers using mass spectrometry techniques such as LC-MS and CE-MS. He continued at UPOL to complete his Ph.D. in Analytical Chemistry, specializing in chiral analysis with HPLC-MS and GC-MS. His academic trajectory culminated in a Habilitation in Physical Chemistry, reflecting his advancements in Raman microscopy, SERS, and mass spectrometry. Dr. Ranc’s education is deeply rooted in analytical and physical chemistry, with a significant emphasis on developing and applying sophisticated separation and detection techniques for complex biological and clinical samples. His academic background is further enriched by international research experiences in Sweden and Switzerland, where he worked on electroanalytical techniques and nanoLC-MS applications for neurotransmitter analysis.

Experience:

Dr. Václav Ranc currently serves as the Head of a Research Group at Palacký University Olomouc, managing a 20-member team focused on cutting-edge nanomaterials and analytical chemistry. He has led the group’s scientific, financial, and personnel management, improving research output by 30%. Previously, he worked as a Research Assistant in Switzerland and at Palacký University, where he developed analytical techniques for clinical and neurological studies using mass spectrometry. His earlier roles include assisting in electrochemical method development at Lund University and clinical toxicology at Faculty Hospital Olomouc. His leadership extends to managing multimillion-CZK budgets and delivering impactful results in EU-funded research projects. Throughout his career, he has seamlessly combined academic excellence with innovation, leading to patented technologies and industrial prototypes, while mentoring young researchers and collaborating with international scientific networks.

Honors & Awards:

Dr. Václav Ranc has received several national and international honors for his scientific excellence. Notable among them is the Golden Medal at the International Invent Arena for the innovative KeyLock authentication system. He also earned the Bronze Prize from MERCK’s Young Analytical Chemists Competition and was a Finalist for the prestigious Shimadzu Prize for Young Analytical Chemists. His awards reflect consistent recognition for his groundbreaking work in analytical chemistry and applied nanotechnology. These accolades underscore his ability to translate complex research into practical applications, particularly in biosensing, authentication systems, and advanced materials. Dr. Ranc’s career is marked by impactful innovations that bridge academic research with industry needs, affirming his role as a thought leader in his field. His awarded projects and patents have contributed significantly to medical diagnostics, material sciences, and anti-counterfeiting technologies.

Research Focus:

Dr. Ranc’s research focuses on analytical chemistry, nanotechnology, and biosensing. He specializes in Raman spectroscopy (including SERS), LC/GC-MS, and the development of plasmonic and electronic nanosensors. His work bridges basic science and applied innovation, emphasizing the synthesis of nanoparticles, development of authenticity verification systems, and detection of biomarkers in clinical diagnostics. His contributions to surface-enhanced Raman spectroscopy have led to the development of patented methods and tools, including test strips and analytical systems. Dr. Ranc’s interdisciplinary approach combines analytical method development, data analysis using Python, R, and Matlab, and project management of EU-funded research. His current Horizon Europe projects focus on medical applications of nanotechnology, contributing to improved diagnostics, drug delivery systems, and authenticity verification. Through collaborations with European research institutions and industries, Dr. Ranc is pushing the boundaries of next-gen biomedical and analytical technologies.

Publication Top Notes:

  1. Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy

  2. Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450

  3. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy

  4. Polymer-Based Graphene Derivatives and Microwave-Assisted Silver Nanoparticles Decoration as a Potential Antibacterial Agent

  5. New Limits for Stability of Supercapacitor Electrode Material Based on Graphene Derivative

  6. Label-free Determination of Prostate Specific Membrane Antigen in Human Whole Blood by Magnetically Assisted SERS

  7. Cyanographene and Graphene Acid: Emerging Derivatives Enabling High-Yield and Selective Functionalization of Graphene

  8. Detection of Prosthetic Joint Infection Based on Magnetically Assisted Surface Enhanced Raman Spectroscopy

  9. Functional Nanosheet Synthons by Covalent Modification of Transition-Metal Dichalcogenides

  10.  Nanoporous Nitrogen-Doped Graphene Oxide/Nickel Sulfide Composite Sheets for Hydrogen and Oxygen Evolution

Conclusion:

In conclusion, Dr. Václav Ranc is an exceptional candidate for the Best Researcher Award, demonstrating a rare synergy of academic excellence, applied innovation, and impactful leadership. His contributions to analytical chemistry and nanotechnology have advanced both scientific understanding and practical diagnostic solutions. His impressive publication record, international collaborations, patent portfolio, and success in leading multimillion-euro projects set him apart as a researcher of outstanding merit. With minor expansion into global research programs and commercialization efforts, Dr. Ranc is poised to further amplify his already significant impact. For his sustained contributions to science, his ability to lead and innovate, and his commitment to solving real-world problems through chemistry and nanotechnology, Dr. Václav Ranc is highly deserving of the Best Researcher Award.

Lei Shi | Tumorigenesis | Distinguished Scientist Award

Published on by Cell Biologist

Mr. Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi, Lanzhou University, China

Dr. Lei Shi is a distinguished cancer biologist and molecular pathologist, currently serving as a Professor and Group Leader at the School of Public Health, Lanzhou University, China. With an international career spanning Germany, the UK, and China, Dr. Shi has significantly contributed to our understanding of long non-coding RNAs (lncRNAs), KRAS-mediated tumorigenesis, and lung cancer biology. He earned his Ph.D. from Ludwig Maximilian University of Munich, and completed postdoctoral training at the CRUK Manchester Institute, one of the world’s premier cancer research centers. His interdisciplinary research bridges cancer signaling, immunotherapy, and molecular genetics. Dr. Shi has been the recipient of multiple national and international grants and has authored numerous high-impact publications in journals such as Nature Communications, Molecular Cancer, and Cell Death & Differentiation. His research plays a pivotal role in advancing personalized cancer therapy and diagnostics, making him a strong contender for the Distinguished Scientist Award.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Extensive Expertise in Tumorigenesis
    Dr. Shi has built a deep and consistent research track record in lung cancer biology, KRAS signaling, and non-coding RNAs—critical areas in modern tumorigenesis research. His work spans oncogene-driven pathways, epigenetics, and RNA biology, which are all highly relevant to the theme of this award.

  2. Strong International Training and Collaborations
    His academic path includes a Ph.D. in Germany (LMU Munich), a postdoctoral fellowship in the UK (University of Manchester/Cancer Research UK), and leadership in China—demonstrating international impact and collaboration.

  3. Proven Research Leadership
    As a Group Leader and Professor at Lanzhou University, Dr. Shi has led grants from both national and provincial Chinese funding bodies, showcasing strong institutional leadership and research independence.

  4. High-Impact Publications
    Dr. Shi has multiple first-author and corresponding-author publications in top-tier journals like Nature Communications, Molecular Cancer, Cell Death & Differentiation, Cancer Research, and others. This indicates a sustained contribution to scientific knowledge with measurable impact.

  5. Focus on Translational Relevance
    His work on KRAS-mediated tumorigenesis, lncRNAs in cancer, microRNA regulation, and drug resistance directly contributes to potential cancer therapies and diagnostics, aligning with the translational emphasis of many distinguished awards.

  6. Mentorship and Emerging Talent Development
    Multiple publications list junior co-authors under his supervision, showing that he actively mentors young scientists and builds collaborative research teams.

Areas for Improvement:

  1. Broader Recognition in Global Awards
    While Dr. Shi has an impressive research footprint, there is limited mention of international awards, editorial roles, or keynote presentations, which are often considered markers of distinguished global leadership.

  2. Clinical Translation or Patents
    The profile would benefit from stronger clinical application indicators, such as patents, clinical trials, or biotechnology translation, to further demonstrate real-world impact.

  3. Broader Research Diversification
    Although his expertise is deep in KRAS and RNA biology, engaging with emerging areas like AI in cancer research, organoid modeling, or immune-oncology interfaces could amplify his multidisciplinary influence.

Education:

Dr. Lei Shi’s academic journey is deeply rooted in life sciences and molecular pathology. He obtained his Bachelor’s degree in Veterinary Medicine (2003–2007) from Heibei North University, China, followed by a Master’s degree (2007–2010) in Agricultural Microbiology at Huazhong Agricultural University, where he developed his early interest in pathogenic mechanisms. He then pursued his Ph.D. (Dr.rer.nat) in Molecular Pathology (2011–2014) at the Ludwig Maximilian University of Munich, Germany, under the mentorship of Prof. Dr. Heiko Hermeking. His doctoral research explored the transcriptional regulation of tumor suppressors and oncogenes. This academic progression built a solid foundation in molecular oncology, leading to a postdoctoral fellowship (2015–2021) at the Cancer Research UK Manchester Institute and Lung Cancer Centre of Excellence, UK. Dr. Shi’s diverse education has provided him with a global and translational perspective on cancer biology, strengthening his leadership in molecular oncology research today.

Professional Experience:

Dr. Lei Shi is a Professor and Group Leader (2021–present) at Lanzhou University, where he heads translational cancer biology research within the School of Public Health. Prior to this, he held a prestigious Postdoctoral Research Fellow role (2015–2021) at the Cancer Research UK Manchester Institute, affiliated with The University of Manchester. There, he conducted cutting-edge research on KRAS-driven lung cancers, drug resistance mechanisms, and RNA therapeutics. Earlier, he was a Ph.D. researcher (2011–2014) at Ludwig Maximilian University of Munich, delving into the regulatory roles of p53 and lncRNAs. His professional experience reflects a continuum of cancer research from fundamental science to translational applications. Dr. Shi’s team at Lanzhou University is now exploring new therapeutic targets for non-small cell lung cancer and virus-associated cancers. He has secured multiple prestigious national and international grants and is actively mentoring the next generation of cancer researchers in China.

Research Focus:

Dr. Lei Shi’s research centers on the molecular mechanisms of cancer development and progression, with a primary focus on long non-coding RNAs (lncRNAs), KRAS oncogene signaling, and RNA-based therapeutic strategies. His lab investigates how lncRNAs modulate gene expression, interact with microRNAs, and influence tumor microenvironment and immune response, particularly in non-small cell lung cancer (NSCLC) and virus-related malignancies. Dr. Shi is also exploring transcriptional feedback loops, including interactions between HIF1A-AS2 and MYC, to unravel how oncogenic pathways fuel metastasis. His postdoctoral work revealed KRAS-induced microRNA regulation, significantly advancing the understanding of RNA biology in cancer. Dr. Shi’s research integrates bioinformatics, functional genomics, and clinical samples to identify novel biomarkers and therapeutic targets. His contributions are paving the way for precision oncology, making a significant impact on early diagnosis, patient stratification, and drug resistance profiling in solid tumors, especially lung cancer.

Publications Top Notes: 

  1. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy – Molecular Cancer (2025)

  2. Long non-coding RNA-encoded micropeptides: functions, mechanisms and implications – Cell Death & Discovery (2024)

  3. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy – Cancer Gene Therapy (2023)

  4. Long non-coding RNA HIF1A-As2 and MYC form a double positive feedback loop in NSCLC – Cell Death & Differentiation (2023)

  5. Long non-coding RNAs in virus-related cancers – Reviews in Medical Virology (2022)

  6. Prognostic and immunotherapeutic roles of KRAS in Pan-Cancer – Cells (2022)

  7. A KRAS-responsive long non-coding RNA controls microRNA processing – Nature Communications (2021)

  8. Diverse roles of long non-coding RNA in viral diseases – Reviews in Medical Virology (2020)

  9. Vulnerability of drug-resistant EML4-ALK lung cancer to transcriptional inhibition – EMBO Mol Med (2020)

  10. KRAS induces lung tumorigenesis through microRNAs modulation – Cell Death & Disease (2018)

  11. The immunological and prognostic landscape of TFAP4 in cancer (scRNA-seq study) – Archives of Biochemistry and Biophysics (2025)

Conclusion:

Dr. Lei Shi is highly suitable for the Distinguished Scientist Award in Tumorigenesis Research. His exceptional publication record, international training, leadership in cancer biology, and dedication to translational science make him a standout candidate. With ongoing contributions and future expansion into cross-disciplinary domains, his research trajectory is aligned with the highest standards of scientific distinction.

Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Published on by Cell Biologist

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Mrs. Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Mrs. Marija Gjorgoska | Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana | Slovenia

Marija Gjorgoska is a dedicated biomedical researcher and teaching assistant at the Faculty of Medicine, University of Ljubljana, Slovenia. With a strong background in biochemistry, molecular biology, and bioinformatics, she has contributed significantly to cancer research, focusing on steroid hormone signaling in gynecological cancers. Her scientific work combines analytical expertise in LC-MS/MS with a solid foundation in molecular biology and statistical analysis using R programming. Marija is passionate about advancing clinical diagnostics and cancer treatment through high-precision biomolecular profiling. Her academic journey reflects international exposure through internships in the UK and Macedonia. She is known for her collaborative spirit and commitment to scientific rigor, which has led to multiple high-impact publications. Marija continues to mentor students and contribute to the academic community through her teaching role, making her a rising figure in molecular oncology research.

publication profile:

scopus

Strengths:

  1. High Research Productivity 📈
    Marija Gjorgoska has authored or co-authored 10 peer-reviewed publications in high-impact journals such as Progress in Lipid Research (IF 14.0), Trends in Endocrinology and Metabolism (IF 11.4), and Cancers. Her work shows consistent scientific output, often with first or shared first authorship.

  2. Cutting-Edge Technical Expertise 🔬
    She demonstrates advanced proficiency in LC-MS/MS method development, multi-steroid profiling, and bioinformatics (R programming). This makes her an expert in translational hormone research and biomarker discovery.

  3. Clinical Relevance and Innovation ⚕️
    Her research addresses urgent clinical challenges like endometrial cancer diagnosis and ovarian cancer drug resistance, applying modern analytical techniques combined with machine learning, which positions her at the forefront of personalized medicine.

  4. Recognition and Collaboration 🤝
    She has been awarded prestigious grants (e.g., Society of Endocrinology, UK), collaborated internationally (UK, Macedonia), and contributes to academia as a teaching assistant—all signs of an emerging research leader.

  5. Interdisciplinary Impact 🌐
    Marija effectively integrates molecular biology, biochemistry, analytical chemistry, and computational biology—indicative of her versatility and broad scientific impact.

Areas for Improvement:

  1. Independent Research Leadership
    While she has made substantial contributions as a junior and co-investigator, future work could benefit from establishing herself as a principal investigator or project leader, including securing her own research funding.

  2. Diversification of Research Themes
    Her focus has been predominantly on hormone-related cancers. Expanding into other disease models or mechanisms could broaden her impact and create new collaborative opportunities.

  3. Public Engagement and Outreach
    Enhancing her visibility through conference presentations, science communication, or community health initiatives would further solidify her standing as a leader and advocate for biomedical research.

Education :

Marija Gjorgoska is currently enrolled in a doctoral program in Biomedicine, specializing in Biochemistry and Molecular Biology at the University of Ljubljana. Her academic foundation includes a Master’s degree in Molecular Biology (2018–2021) from the same university, completed with an outstanding GPA of 9.52/10. She also gained international experience through a short-term internship at the University of Birmingham, UK, in 2023, focusing on advanced LC-MS/MS techniques for clinical sample analysis. Earlier in her academic career, she completed a long-term internship at the Research Center for Genetic Engineering and Biotechnology in Skopje, Macedonia (2017), where she worked on genetic diagnostics involving haemoglobinopathies, HPV, HBV, and HCV detection. Her education has consistently emphasized both theoretical knowledge and hands-on laboratory skills, particularly in analytical chemistry, molecular biology, and bioinformatics, all of which shape her current research endeavors in cancer diagnostics and hormonal regulation.

Experience:

Marija Gjorgoska has been actively engaged in research since 2020 as a Research Assistant at the Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana. Her core responsibilities include developing and validating LC-MS/MS analytical methods, conducting proteomic and genetic analyses of cancer tissues, and performing bioinformatic evaluations using R programming. In October 2024, she also began serving as a Teaching Assistant for the course “Principles of Biochemistry,” demonstrating her commitment to education and mentorship. Marija’s prior internships have equipped her with valuable skills in prenatal and infectious disease diagnostics. Her research contributions span experimental planning, scientific writing, and instrument maintenance, establishing her as a versatile scientist. Her collaborative projects with international researchers and clinicians further underline her strength in translational biomedical research. This combination of teaching, laboratory, and analytical expertise supports her growing influence in molecular oncology.

Awards and Honors:

Marija Gjorgoska has been recognized for both academic and research excellence. In 2023, she was awarded the Practical Skills Grant by the Society of Endocrinology, UK, enabling her to undergo advanced training in LC-MS/MS at the University of Birmingham. Earlier, in 2021, she received the Krka Recognition with Special Praise for her Master’s thesis, highlighting her early promise as a researcher in molecular biology. Her scientific publications have appeared in top-tier journals such as Progress in Lipid Research and Trends in Endocrinology and Metabolism, some with impact factors exceeding 14.0. Notably, she earned shared first co-authorship in Methods in Enzymology for her work on enzymatic assay development. These accolades reflect her technical excellence, originality, and scientific contributions in the field of steroid metabolism and gynecological cancers. Marija’s achievements distinguish her as a young researcher with significant impact and high potential for further contributions to science and medicine.

Research Focus :

Marija Gjorgoska’s research focuses on the role of steroid hormones in the development and progression of gynecological cancers, particularly endometrial and ovarian cancers. Her work integrates analytical chemistry (LC-MS/MS), bioinformatics, and molecular biology to uncover diagnostic and prognostic biomarkers. She has developed multi-steroid profiling techniques to differentiate between normal and cancerous tissues, aiding early diagnosis. Marija’s studies also address the pre-receptor regulation of androgenic and estrogenic hormones, exploring their signaling dynamics at the tissue level. Using tools such as Mendelian randomization, she investigates genetic influences on hormone-related disease risk. Her interdisciplinary approach combines advanced mass spectrometry, statistical modeling, and clinical collaboration to translate bench science into meaningful medical applications. Through high-impact publications, she contributes to understanding hormone metabolism in cancer microenvironments, with the goal of informing targeted therapies and overcoming drug resistance. Her work is critical for advancing personalized medicine in hormone-driven malignancies.

Publications Top Notes:

  1. 📘 From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling – Progress in Lipid Research, 2024

  2. 📘 Integration of androgen hormones in endometrial cancer biology – Trends in Endocrinology and Metabolism, 2022

  3. 📘 Steroid sulfatase and sulfotransferases in gynecological cancers: current status and perspectives – Essays in Biochemistry, 2024

  4. 📘 Estrogens and the Schrödinger’s cat in the ovarian tumor microenvironment – Cancers, 2021

  5. 📘 Multi-Steroid Profiling and Machine Learning Reveal Androgens as Biomarkers for Endometrial Cancer – Cancers, 2025

  6. 📘 Simultaneous measurement of 17 endogenous steroid hormones by LC-MS/MS – J. of Steroid Biochemistry and Molecular Biology, 2024

  7. 📘 11-oxyandrogens in normal vs. cancerous endometrium – Frontiers in Endocrinology, 2024

  8. 📘 Targeting estrogen metabolism to overcome platinum resistance in ovarian cancer – Biomedicine & Pharmacotherapy, 2024

  9. 📘 Effect of androgens on risk of endometriosis sub-phenotypes and ovarian neoplasms – J. of Steroid Biochemistry and Molecular Biology, 2024

  10. 📘 Enzymatic assays for 17β-HSD types 1 and 2 using mass spectrometry – Methods in Enzymology, 2023

Conclusion:

Marija Gjorgoska is a highly promising early-career researcher with a strong and growing international publication record, deep technical expertise in analytical biochemistry, and a clear focus on clinically relevant research. Her integration of hormonal pathway analysis with state-of-the-art analytical methods has already contributed valuable insights to the field of gynecological oncology. She has the academic rigor, curiosity, and collaborative drive essential for impactful science.

In my opinion, she is a highly suitable candidate for the Best Researcher Award. Continued mentorship and support toward independent research leadership will elevate her even further in the years to come.

Tao Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Tao Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Tao Zhang, South China Normal University, China

Dr. Tao Zhang is a distinguished Professor at the College of Biophotonics, South China Normal University, where he has been advancing the frontiers of chemical biology and phototheranostics. With a keen focus on developing innovative optical probes and imaging techniques for tumor diagnosis and treatment, Dr. Zhang has made significant contributions to the field of lanthanide chemistry and biomedical imaging. His academic journey spans from Ningbo University (MPhil) to earning his Ph.D. in Chemistry from Hong Kong Baptist University. As a corresponding author on numerous high-impact publications and a recipient of multiple prestigious provincial awards, Dr. Zhang has earned recognition for both research excellence and academic leadership. He is actively involved in interdisciplinary collaborations, producing over 40 peer-reviewed publications in journals such as Nature Communications, PNAS, JACS, and Advanced Science. His ongoing work addresses critical challenges in imaging-guided therapies for cancer under hypoxic and complex microenvironment conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📈 Outstanding Research Output
    Dr. Zhang has published over 40 peer-reviewed articles in top-tier journals such as Nature Communications, Advanced Science, JACS, ACS Nano, and PNAS. These works cover cutting-edge topics in photodynamic therapy, tumor imaging, and nanotechnology—key areas in modern biomedical research.

  2. 🧪 Innovation in Biomedical Chemistry
    He has demonstrated consistent originality by designing oxygen-independent Type I pro-photosensitizers, reversible ratiometric photoacoustic probes, and multimodal imaging nanoplatforms, all of which target real-world challenges in hypoxic tumor environments.

  3. 🌏 National Recognition
    His research excellence has been recognized by prestigious awards such as the Special Support Program for Young Top-notch Talents of Guangdong Province and the Pearl River Science and Technology Rising Star of Guangzhou, both in 2018.

  4. 🎯 Multidisciplinary Expertise
    With a strong background in lanthanide chemistry, chemical biology, and optical imaging, Dr. Zhang successfully bridges multiple fields, demonstrating a holistic approach to solving biomedical challenges.

  5. 📚 Leadership Role
    As a corresponding author on many publications, he plays a leading role in both research direction and execution. His progression from Assistant to Full Professor between 2014 and 2021 further reflects his capability as a research leader.

🛠️ Areas for Improvement:

  1. 🌐 International Collaborations & Visibility
    While Dr. Zhang has co-authored with international researchers, expanding his global collaborative network through joint grants, keynote talks, or leadership in international consortia could further enhance his profile.

  2. 👨‍🏫 Public Outreach & Technology Transfer
    Increasing efforts in public science communication, patenting innovations, or transitioning lab technologies into clinical trials could strengthen his case for broader societal impact.

  3. 📢 Social & Digital Engagement
    A higher digital or social media presence (e.g., ResearchGate, Google Scholar metrics, professional website updates) would make his research more visible to the global community and potential collaborators.

🎓 Education:

Dr. Tao Zhang embarked on his academic career with an MPhil in Inorganic Chemistry from Ningbo University (2006–2009), where he conducted research under Professor Hongze Liang. He furthered his education by pursuing a Ph.D. in Chemistry at Hong Kong Baptist University (2009–2013), mentored by Professors Wai-Kwok Wong and Ka-Leung Wong. His doctoral research focused on lanthanide coordination chemistry and bioimaging, setting a strong foundation for his future innovations in photodynamic therapy and tumor diagnostics. These formative years not only shaped his technical expertise in spectroscopy and nanomaterials but also cultivated a rigorous research ethic that has carried through his academic trajectory. His education was marked by cross-disciplinary training in synthetic chemistry, photophysics, and biological applications, providing him with a broad and robust skill set that continues to support his ongoing exploration in chemical biology and optical probes for clinical imaging and therapeutic interventions.

💼 Experience:

Dr. Zhang’s academic career at South China Normal University’s College of Biophotonics began in 2014 as an Assistant Professor. He was promoted to Associate Professor in 2017 and then to full Professor in 2021. Throughout his academic appointments, Dr. Zhang has led innovative research in tumor imaging, photothermal therapy, and optical diagnostics, establishing a productive research group known for creative nanoprobe design and translational research. His lab has secured multiple research grants and frequently collaborates with international researchers, combining chemical innovation with biomedical applications. Dr. Zhang has mentored graduate students and postdocs, many of whom have gone on to prestigious research positions. His steady academic progression reflects both his research productivity and leadership in the field of phototheranostics. Over the years, his expertise has positioned him at the forefront of integrating nanotechnology and chemistry into next-generation diagnostic and therapeutic platforms for treating cancer and understanding tumor microenvironments.

🏆 Awards and Honors:

Dr. Tao Zhang has received multiple prestigious awards that underscore his exceptional research contributions and scientific leadership. In 2018, he was honored with the Special Support Program for Young Top-notch Talents of Guangdong Province, recognizing his pioneering work in optical molecular probes for cancer imaging. That same year, he also received the Pearl River Science and Technology Rising Star of Guangzhou, further validating the impact and innovation of his interdisciplinary research in chemical biology. These accolades highlight his rising prominence as a researcher capable of translating basic chemical discoveries into practical medical technologies. He is consistently invited to contribute as a corresponding author in top-tier journals, reflecting the high regard his peers have for his scientific insight and rigor. These honors not only reflect personal achievement but also enhance the prestige of the College of Biophotonics at South China Normal University, where he continues to lead cutting-edge research.

🔍 Research Focus:

Dr. Tao Zhang’s research focuses on the convergence of Chemical Biology, Lanthanide Chemistry, and Optical Imaging Technologies for cancer diagnosis and treatment. His main interest lies in developing smart, light-activated nanomaterials and photosensitizers that enable precise imaging and phototherapy, particularly in hypoxic tumor microenvironments. His team is advancing Type I photodynamic therapy agents and oxygen-independent systems, addressing critical limitations in current cancer treatment modalities. Another core area of his research is the creation of upconversion nanoparticles and ratiometric probes for real-time, non-invasive imaging—capable of dual-modality functionality (fluorescence and photoacoustic). Leveraging lanthanide chemistry, Dr. Zhang also contributes to MRI contrast agent innovation and multimodal diagnostics. His cross-disciplinary work integrates synthetic chemistry, molecular design, and biological application, offering new avenues for theranostics. His cutting-edge research is published in leading journals, pushing the boundaries of tumor imaging, molecular sensing, and personalized cancer therapy with minimal invasiveness and enhanced specificity.

📚 Publications Top Notes:

  1. 🧬 Totally Caged Type I Pro-Photosensitizer for Oxygen-Independent Synergistic Phototherapy of Hypoxic Tumors – Advanced Science, 2024

  2. 🔁 Switching the NIR Upconversion of Nanoparticles for Orthogonal Activation of Photoacoustic Imaging and Phototherapy – Nature Communications, 2022

  3. 🧪 Dynamic-Reversible Photoacoustic Probe for Continuous Ratiometric Sensing and Imaging of Redox Status In Vivo – JACS, 2019

  4. 🎯 In Vivo Imaging-Guided Photothermal/Photoacoustic Synergistic Therapy with Tumor-Targeting Nanoparticles – ACS Nano, 2017

  5. 💥 In Vivo Selective Cancer-Tracking Gadolinium Eradicator as New-Generation Photodynamic Therapy Agent – PNAS, 2014

  6. 🧫 ROS-Catalytic Self-Amplifying Benzothiophenazine-Based Photosensitive Conjugates for Photodynamic-Immuno Therapy – Biomaterials, 2025

  7. 🧬 A Self-Catalytic UCNP-Based Nanomachine for Highly Sensitive Detection of CTCs – Biosensors and Bioelectronics, 2025

  8. 🔍 An AND-Gate Photoacoustic Probe for Cys and H2S Precise Photoacoustic Sensing in Tumors – Anal. Chem., 2024

  9. 🎨 Single Side-Chain-Modulatory of Hemicyanine for Fluorescence and Photoacoustic Dual-Modality Imaging – Small Methods, 2024

  10. 🌫️ High-Contrast Photoacoustic Imaging of Localized Cysteine in Breast Cancer – Chem. Eur. J., 2024

🧾 Conclusion:

Dr. Tao Zhang is highly suitable for the Best Researcher Award due to his exceptional scholarly output, innovative biomedical applications, and proven academic leadership. His work addresses some of the most critical challenges in cancer diagnostics and therapy using chemical tools and photonic technology.

baofeng wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. baofeng wang | Cancer Cell Biology | Best Researcher Award

Prof. baofeng wang, Department of Radiation Therapy, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an 710004, China, China

Dr. Baofeng Wang is a Professor and Associate Chief Physician at The Second Affiliated Hospital of Xi’an Jiaotong University. He serves as Head of the Abdominal Oncology Group in the Department of Radiation Oncology and is a Master’s Supervisor. Renowned for his expertise in abdominal and liver cancers, Dr. Wang actively contributes to several professional organizations, including the Chinese Society for Radiation Oncology (CSRO). As a reviewer for top journals and a recipient of multiple prestigious research awards, his work integrates clinical excellence with cutting-edge research. He has led three national and provincial-level projects and has authored over 40 scientific articles, with more than 10 published in SCI-indexed journals. His recent work focuses on ferroptosis, immune regulation in cancer, and BNCT treatment planning, marking him as a leading figure in translational oncology research.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Academic and Clinical Leadership:

    • Professor, Associate Chief Physician, and Master’s Supervisor.

    • Head of the Abdominal Oncology Group at a leading national medical institution.

    • Actively leads and shapes treatment protocols in radiation oncology.

  2. Research Productivity and Impact:

    • Authored over 40 scientific publications, with more than 10 indexed in SCI journals.

    • Principal Investigator for 3 major funded research projects.

    • Co-investigator in 5 additional national and provincial projects.

    • Reviewer for high-impact international journals, ensuring scientific rigor in oncology research.

  3. Recognition and Awards:

    • Winner of two First Prizes for Scientific and Technological Progress in Higher Education Institutions.

    • Received a Second Prize from the Shaanxi Provincial Scientific and Technological Progress Awards.

  4. Professional Influence:

    • Holds multiple key positions in national and provincial medical societies, especially within the Chinese Society for Radiation Oncology (CSRO).

    • Active in bridging research, clinical practice, and public health education.

  5. Recent Research Focus:

    • Investigating mechanisms of radioresistance via ferroptosis and cholesterol metabolism.

    • Advancing boron neutron capture therapy (BNCT) planning and immunoregulatory pathways in breast cancer and hepatocellular carcinoma.

⚙️ Areas for Improvement:

  1. Global Collaboration:

    • While domestically influential, expanding international collaborations and partnerships could further elevate the research impact and visibility.

  2. Citation Index and Research Translation:

    • Despite a good number of publications, a higher citation count and more translational outcomes into clinical practice would strengthen the award candidacy further.

  3. Innovation Leadership:

    • Developing patents or pioneering novel therapeutic technologies would add to innovation metrics.

🎓 Education:

Dr. Baofeng Wang received rigorous academic training in the medical sciences, specializing in oncology and radiation therapy. After completing his undergraduate medical degree, he pursued postgraduate studies focused on radiation oncology and tumor biology. His advanced academic pursuits led to a comprehensive understanding of radiobiology, imaging-guided radiotherapy, and molecular oncology. He continuously updates his knowledge through professional development programs and has contributed to both educational and research domains by mentoring postgraduate students. His commitment to academic excellence is evident through his role as a Master’s Supervisor, guiding the next generation of clinical researchers. Dr. Wang’s educational background has equipped him with the skills necessary to integrate evidence-based medicine with innovative research, particularly in the fields of liver cancer and immuno-oncology.

🧪 Professional Experience:

With over 15 years of clinical and academic experience, Dr. Baofeng Wang is a leading figure in the field of radiation oncology. Currently a Professor and Associate Chief Physician, he heads the Abdominal Oncology Group at The Second Affiliated Hospital of Xi’an Jiaotong University. He has been instrumental in developing individualized radiotherapy protocols for complex tumors. His leadership roles in various national and provincial oncology organizations highlight his influence in shaping cancer treatment strategies. He has served as Principal Investigator for several research grants from the National Natural Science Foundation of China and provincial R&D bodies. Additionally, Dr. Wang plays an active role in academic peer review and science promotion in Shaanxi province. His blend of clinical acumen and research proficiency makes him a cornerstone in the advancement of radiotherapy techniques and translational oncology.

🔬 Research Focus:

Dr. Wang’s research focuses on the intersection of radiation oncology, tumor metabolism, and immunoregulation. He investigates how cellular mechanisms such as ferroptosis and cytokine modulation contribute to radioresistance and tumor progression. A major area of interest is the optimization of boron neutron capture therapy (BNCT) treatment planning, aiming to enhance therapeutic outcomes in abdominal cancers. His work also explores the role of tumor-infiltrating immune cells and how factors like interleukin-10 influence immune suppression and therapy response. By integrating molecular diagnostics with imaging-guided radiotherapy, Dr. Wang seeks to improve precision medicine strategies. His translational research aims to convert lab-based discoveries into clinically viable cancer treatments, particularly for liver, breast, and gastrointestinal cancers. Through collaborative and interdisciplinary research, Dr. Wang’s work continues to push boundaries in oncology innovation.

📚 Publications Top Notes:

  1. 🧬 Recent research progress of BNCT treatment planning system

  2. 🔗 SCARB1 links cholesterol metabolism-mediated ferroptosis inhibition to radioresistance in tumor cells

  3. 🎯 BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

  4. 🛡️ Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

📌 Conclusion:

Dr. Baofeng Wang exemplifies the qualities of an exceptional clinical researcher, balancing leadership, clinical service, and impactful research. His contributions to radiation oncology—particularly in abdominal and liver cancers—along with national-level recognition and funding, make him a highly suitable and competitive candidate for the Best Researcher Award. Continued expansion of his international footprint and translational outputs would position him even more prominently on the global stage.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

  1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

  2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

  3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

  4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

  5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

  6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.